Skip to content

Press

Portfolio-Media Coverage
NIDO-361 by Nido Biosciences for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy): Likelihood of Approval
September 11, 2023 Sep 11, 2023 Pharmaceutical Technology
Portfolio-Media Coverage
Resiquimod by SURGE Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
September 11, 2023 Sep 11, 2023 Pharmaceutical Technology
Portfolio-Media Coverage
Companies To Watch: Nido Biosciences
September 1, 2023 Sep 1, 2023 Life Sciences Leader
Portfolio-Media Coverage
Surge receives $32 million in series B
July 23, 2023 Jul 23, 2023 Chemical & Engineering News
Portfolio-Media Coverage
SURGE – US startup bags $32 million to blend cancer surgery and immunotherapy
July 20, 2023 Jul 20, 2023 Outsourcing Pharma
Portfolio-Media Coverage
SURGE Therapeutics secures $32m to advance intraoperative immunotherapy
July 20, 2023 Jul 20, 2023 NS Healthcare
Portfolio-Media Coverage
Immunotherapy during surgery? Surge Therapeutics nabs $32M to expand clinical plans after first dosing
July 19, 2023 Jul 19, 2023 Endpoints
Portfolio-Media Coverage
SURGE – This Startup Just Raised $32 Million To Keep Cancers From Recurring After Surgery
July 19, 2023 Jul 19, 2023 Forbes
Portfolio-Media Coverage
Surge Therapeutics Raises $32M in Series B Financing
July 19, 2023 Jul 19, 2023 FinSMEs
Portfolio-Media Coverage
July 19 Quick Takes: Surge Therapeutics Inc. raised a $32 million series B round
July 19, 2023 Jul 19, 2023 Biocentury